NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $47.00 Consensus Price Target from Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $47.00.

Several brokerages recently issued reports on NAMS. Citigroup lifted their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Leerink Partners reissued an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Needham & Company LLC raised their target price on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st.

Insider Buying and Selling

In related news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the transaction, the insider directly owned 73,481 shares of the company’s stock, valued at approximately $2,443,243.25. This trade represents a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Louise Frederika Kooij sold 75,117 shares of the business’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the completion of the sale, the chief accounting officer owned 15,000 shares in the company, valued at $543,150. This represents a 83.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 298,647 shares of company stock valued at $10,236,050. 20.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Capital World Investors lifted its holdings in shares of NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after acquiring an additional 1,434,986 shares during the last quarter. Jennison Associates LLC raised its position in NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares during the period. Duquesne Family Office LLC raised its position in NewAmsterdam Pharma by 131.2% during the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Finally, Maverick Capital Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 178.8% in the 2nd quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock worth $27,742,000 after purchasing an additional 982,405 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $32.06 on Friday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The company has a market capitalization of $3.64 billion, a P/E ratio of -15.64 and a beta of 0.06. The company has a fifty day moving average of $34.39 and a 200 day moving average of $31.61.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. Analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.